Discover
LUNG
Pulmonx Corporation
1.47
2 x 1.07
2 x 1.68
bid
ask
+
0.17
13.08%
2 @ 04:00 PM
1.49 +0.02 (1.36%)
| Ytd | -33.48% | |
| 1y | -45.35% |
1.30
day range
1.50
1.13
52 week range
3.88
| Open | 1.30 | Prev Close | 1.30 | Low | 1.30 | High | 1.50 | Mkt Cap | 62.09M |
| Vol | 357.33K | Avg Vol | 483.77K | EPS | -1.30 | P/E | N/A | Forward P/E | -3.91 |
| Beta | 0.68 | Short Ratio | 3.62 | Inst. Own | 94.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-29 | 50-d Avg | 1.38 | 200-d Avg | 1.64 | 1yr Est | 11.92 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-10-30 | 2024-09 | -0.43 | -0.36 | 0.07 | 16.28% |
| 2024-07-31 | 2024-06 | -0.41 | -0.39 | 0.02 | 4.88% |
| 2024-07-31 | 2024-06 | -0.41 | N/A | N/A | N/A |
| 2024-05-01 | 2024-03 | -0.43 | -0.36 | 0.07 | 16.28% |
| 2024-05-01 | 2024-03 | -0.43 | N/A | N/A | N/A |
| 2024-02-21 | 2023-12 | -0.39 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-11 | Wells Fargo | Upgrade | Equal-Weight | Equal-Weight |
| 2024-12-11 | Citigroup | Downgrade | Buy | Neutral |
| 2024-10-31 | Stifel | Upgrade | Buy | Buy |
| 2024-08-01 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2024-08-01 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2024-08-01 | Wells Fargo | Upgrade | Equal-Weight | Equal-Weight |
Profile
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-02 | BURNS THOMAS WILLIAM | Director | 36.25K | Stock Award(Grant) |
| 2024-06-02 | FERRARI RICHARD M | Director | 57.87K | Stock Award(Grant) |
| 2024-06-02 | FLORIN DANIEL P | Director | 56.76K | Stock Award(Grant) |
| 2024-11-21 | FRENCH GLENDON E III | Director | 1.07M | Sale |
| 2024-12-01 | LEHMAN DAVID AARON | General Counsel | 197.85K | Sale |
| 2024-06-02 | MEAD DANA G JR | Director | 66.64K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | FMR, LLC | 5.87M | 36.76M | 14.87% |
| 2024-09-29 | Primecap Management Company | 5.68M | 35.53M | 14.37% |
| 2024-09-29 | Morgan Stanley | 3.79M | 23.72M | 9.60% |
| 2024-09-29 | Blackrock Inc. | 2.80M | 17.50M | 7.08% |
| 2024-09-29 | Vanguard Group Inc | 2.28M | 14.27M | 5.77% |
| 2024-09-29 | Deutsche Bank Aktiengesellschaft | 1.12M | 7.02M | 2.84% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Primecap Odyssey Aggressive Growth Fund | 3.86M | 24.17M | 9.78% |
| 2024-08-30 | Fidelity Small Cap Growth Fund | 1.49M | 9.35M | 3.78% |
| 2024-10-30 | Fidelity Select Portfolios - Pharmaceuticals | 1.43M | 8.96M | 3.63% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.16M | 7.27M | 2.94% |
| 2024-10-30 | iShares Russell 2000 ETF | 978.93K | 6.13M | 2.48% |
| 2024-08-30 | Fidelity Advisor Small Cap Fund | 832.40K | 5.21M | 2.11% |